EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieOpen Access

Is an extended dose of subcutaneous nadroparin anticoagulation equally safe and feasible compared to unfractionated heparin anticoagulation during extracorporeal membrane oxygenation in critically ill COVID-19 patients?

Paweł Piwowarczyk, Marta Szczukocka, Agata Uchacz, Paweł Kutnik, Tomasz Czarnik, Mirosław Czuczwar, Michał Borys

Anaesthesiology Intensive Therapy · 2025

DOI: 10.5114/ait/202605 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Anaesthesiology Intensive Therapy, 2025. Verfasst von Paweł Piwowarczyk und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Institute of Medical Sciences, The John Paul II Catholic University of Lublin, Poland. Hauptthemen laut MEDLINE: Anticoagulants, COVID-19 Drug Treatment, Extracorporeal Membrane Oxygenation, Heparin. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Unfractionated heparin (UFH) is the traditional anticoagulant of choice in critically ill COVID-19 patients requiring extracorporeal membrane oxygenation (ECMO). Nadroparin, a low molecular weight heparin, potentially offers advantages such as predictable pharmacokinetics and reduced bleeding risks compared to UFH, with complex pharmacokinetics, influencing activated partial thromboplastin and causing substantial haemorrhagic risks. Bleeding, the most common adverse event during ECMO, is associated by many with increased activated partial thromboplastin time. Material and methods This retrospective, bicentric analysis involved 38 consecutive ECMO-supported COVID-19 patients from two Polish hospitals. The study compared 27 patients receiving UFH and 11 patients treated with 5700 IU of nadroparin administered subcutaneously twice daily. Thrombotic and haemorrhagic complications were assessed to determine the safety and feasibility of each anticoagulant.

Results

Resistance to flow throughout the therapy in the ECMO membrane oxygenator was significantly lower in the group anticoagulated with UFH (1.74 mmHg × minute × L–1 [1.38–2.6] vs. 6.13 mmHg × minute × L–1 [5.93–14.81]; P < 0.001). However, the number of transfused red blood cell packs in the aforementioned group was significantly greater (10 units [5–17] vs. 4 units [2–8]; P = 0.027), and the haemoglobin level after ECMO therapy was significantly lower (7.8 g dL–1 [6.9–8.8] vs. 10.2 g dL–1 [8.5–12.2]; P = 0.003). Moreover, there was a higher number of life-threatening events in the UFH group.

Conclusions

UFH anticoagulation may provide better flow optimization in the oxygenator, but the risk of life-threatening bleeding may increase. The present findings need to be fully elucidated in prospective studies on a larger critically ill population supported with respiratory ECMO.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsCOVID-19 Drug TreatmentExtracorporeal Membrane OxygenationHeparinNadroparinAdultAgedFemaleHumansMaleMiddle AgedCOVID-19Critical IllnessFeasibility StudiesHemorrhageInjections, SubcutaneousRetrospective Studies

Stichwörter der Autor:innen

COVID-19ECMOanticoagulationextendedextracorporealheparinnadroparinoxygenationrespiratoryunfractionated

Substanzen

AnticoagulantsHeparinNadroparin

Autor:innen und Institutionen

  • Faculty of Medicine, Institute of Medical Sciences, The John Paul II Catholic University of Lublin, Poland.
  • Department of Anaesthesiology and Intensive Care, Opole University Hospital, Poland.
  • Department of Anaesthesiology and Intensive Care, Institute of Medical Sciences, University of Opole, Poland.
  • Department of Anesthesiology and Critical Care, Specialized Hospital, Gorzow Wielkopolski, Poland.

Zitieren

APA

Piwowarczyk, P., Szczukocka, M., Uchacz, A., Kutnik, P., Czarnik, T., Czuczwar, M., & Borys, M. (2025). Is an extended dose of subcutaneous nadroparin anticoagulation equally safe and feasible compared to unfractionated heparin anticoagulation during extracorporeal membrane oxygenation in critically ill COVID-19 patients?. Anaesthesiology Intensive Therapy. https://doi.org/10.5114/ait/202605

Vancouver

Piwowarczyk P, Szczukocka M, Uchacz A, Kutnik P, Czarnik T, Czuczwar M, et al. Is an extended dose of subcutaneous nadroparin anticoagulation equally safe and feasible compared to unfractionated heparin anticoagulation during extracorporeal membrane oxygenation in critically ill COVID-19 patients?. Anaesthesiology Intensive Therapy. 2025. doi:10.5114/ait/202605

BibTeX
@article{Piwowarczyk2025,
  author = {Piwowarczyk, Paweł and Szczukocka, Marta and Uchacz, Agata and Kutnik, Paweł and Czarnik, Tomasz and Czuczwar, Mirosław and Borys, Michał},
  title = {Is an extended dose of subcutaneous nadroparin anticoagulation equally safe and feasible compared to unfractionated heparin anticoagulation during extracorporeal membrane oxygenation in critically ill COVID-19 patients?},
  journal = {Anaesthesiology Intensive Therapy},
  year = {2025},
  doi = {10.5114/ait/202605}
}
Kostenlos starten →